# Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

> **NCT00281008** · PHASE2 · COMPLETED · sponsor: **Kastle Therapeutics, LLC** · enrollment: 44 (actual)

## Conditions studied

- Hypercholesterolemia, Familial

## Interventions

- **DRUG:** ISIS 301012 or Placebo
- **DRUG:** ISIS 301012 or Placebo
- **DRUG:** ISIS 301012 or Placebo
- **DRUG:** ISIS 301012 or Placebo

## Key facts

- **NCT ID:** NCT00281008
- **Lead sponsor:** Kastle Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-07
- **Final completion:** 2007-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2016-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281008, "Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00281008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*